Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NCKAP1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NCKAP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NCKAP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NCKAP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NCKAP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NCKAP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NCKAP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NCKAP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NCKAP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00080644 | Colorectum | FAP | regulation of actin polymerization or depolymerization | 52/2622 | 188/18723 | 6.62e-07 | 3.20e-05 | 52 |
GO:00512584 | Colorectum | FAP | protein polymerization | 73/2622 | 297/18723 | 7.11e-07 | 3.32e-05 | 73 |
GO:00308324 | Colorectum | FAP | regulation of actin filament length | 52/2622 | 189/18723 | 7.91e-07 | 3.64e-05 | 52 |
GO:00072652 | Colorectum | FAP | Ras protein signal transduction | 80/2622 | 337/18723 | 9.61e-07 | 4.33e-05 | 80 |
GO:00313463 | Colorectum | FAP | positive regulation of cell projection organization | 82/2622 | 353/18723 | 1.78e-06 | 7.35e-05 | 82 |
GO:00322734 | Colorectum | FAP | positive regulation of protein polymerization | 40/2622 | 138/18723 | 3.55e-06 | 1.26e-04 | 40 |
GO:00308384 | Colorectum | FAP | positive regulation of actin filament polymerization | 31/2622 | 99/18723 | 7.77e-06 | 2.32e-04 | 31 |
GO:00975814 | Colorectum | FAP | lamellipodium organization | 29/2622 | 90/18723 | 8.11e-06 | 2.40e-04 | 29 |
GO:19027454 | Colorectum | FAP | positive regulation of lamellipodium organization | 16/2622 | 37/18723 | 1.44e-05 | 3.80e-04 | 16 |
GO:19027434 | Colorectum | FAP | regulation of lamellipodium organization | 20/2622 | 54/18723 | 2.09e-05 | 5.05e-04 | 20 |
GO:00105923 | Colorectum | FAP | positive regulation of lamellipodium assembly | 13/2622 | 29/18723 | 5.81e-05 | 1.15e-03 | 13 |
GO:00300322 | Colorectum | FAP | lamellipodium assembly | 22/2622 | 72/18723 | 2.31e-04 | 3.25e-03 | 22 |
GO:00105913 | Colorectum | FAP | regulation of lamellipodium assembly | 15/2622 | 42/18723 | 3.51e-04 | 4.47e-03 | 15 |
GO:00308663 | Colorectum | FAP | cortical actin cytoskeleton organization | 14/2622 | 40/18723 | 6.94e-04 | 7.50e-03 | 14 |
GO:00166012 | Colorectum | FAP | Rac protein signal transduction | 14/2622 | 42/18723 | 1.20e-03 | 1.14e-02 | 14 |
GO:00308653 | Colorectum | FAP | cortical cytoskeleton organization | 18/2622 | 61/18723 | 1.30e-03 | 1.20e-02 | 18 |
GO:00450104 | Colorectum | FAP | actin nucleation | 16/2622 | 52/18723 | 1.46e-03 | 1.31e-02 | 16 |
GO:00343144 | Colorectum | FAP | Arp2/3 complex-mediated actin nucleation | 13/2622 | 39/18723 | 1.78e-03 | 1.54e-02 | 13 |
GO:01200323 | Colorectum | FAP | regulation of plasma membrane bounded cell projection assembly | 39/2622 | 186/18723 | 5.84e-03 | 3.73e-02 | 39 |
GO:00511253 | Colorectum | FAP | regulation of actin nucleation | 10/2622 | 30/18723 | 5.90e-03 | 3.75e-02 | 10 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa051324 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa051304 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa048104 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa051325 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa051305 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa048105 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCKAP1 | SNV | Missense_Mutation | | c.2730G>C | p.Leu910Phe | p.L910F | Q9Y2A7 | protein_coding | deleterious(0) | possibly_damaging(0.548) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
NCKAP1 | SNV | Missense_Mutation | | c.1118N>G | p.Lys373Arg | p.K373R | Q9Y2A7 | protein_coding | deleterious(0.01) | benign(0.315) | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
NCKAP1 | SNV | Missense_Mutation | | c.1186N>T | p.Asp396Tyr | p.D396Y | Q9Y2A7 | protein_coding | deleterious(0.02) | probably_damaging(0.918) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
NCKAP1 | SNV | Missense_Mutation | novel | c.2348N>G | p.Asp783Gly | p.D783G | Q9Y2A7 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCKAP1 | SNV | Missense_Mutation | | c.1372N>A | p.Cys458Ser | p.C458S | Q9Y2A7 | protein_coding | deleterious(0) | benign(0.348) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCKAP1 | SNV | Missense_Mutation | | c.3332N>A | p.Ser1111Tyr | p.S1111Y | Q9Y2A7 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCKAP1 | SNV | Missense_Mutation | | c.464N>A | p.Arg155Gln | p.R155Q | Q9Y2A7 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCKAP1 | SNV | Missense_Mutation | | c.1582C>T | p.His528Tyr | p.H528Y | Q9Y2A7 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NCKAP1 | SNV | Missense_Mutation | | c.2776N>A | p.Ala926Thr | p.A926T | Q9Y2A7 | protein_coding | tolerated(0.16) | benign(0.112) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NCKAP1 | SNV | Missense_Mutation | novel | c.1937N>T | p.Ala646Val | p.A646V | Q9Y2A7 | protein_coding | tolerated(0.23) | possibly_damaging(0.793) | TCGA-D8-A27W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |